Market Research Report
Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||484631|
|Published||Content info||209 Pages
Delivery time: 1-2 business days
|Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018|
|Published: September 26, 2018||Content info: 209 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.
Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 4, 9 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 9, 2, 5 and 4 molecules, respectively.
Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.